$HTGM Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in HTG MOLECULAR DIAGNOSTICS, INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in HTG MOLECULAR DIAGNOSTICS, INC. Get notifications about new insider transactions in HTG MOLECULAR DIAGNOSTICS, INC for free.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Oct 18 2017 | HTGM | HTG MOLECULAR DIAG ... | McMeans Shaun D | VP, Finance & Admin ... | Sell | S | 2.27 | 946 | 2,148 | 44,193 | 45.1 K to 44.2 K (-2.10 %) |
| Aug 28 2017 | HTGM | HTG MOLECULAR DIAG ... | McMeans Shaun D | VP, Finance & Admin ... | Grant | A | 1.99 | 2,500 | 4,975 | 45,139 | 42.6 K to 45.1 K (+5.86 %) |
| Aug 25 2017 | HTGM | HTG MOLECULAR DIAG ... | Novo Holdings A/S | 10% Owner | Sell | S | 1.75 | 720,214 | 1,260,591 | 0 | 720.2 K to 0 (-100.00 %) |
| Aug 25 2017 | HTGM | HTG MOLECULAR DIAG ... | Novo Holdings A/S | 10% Owner | Sell | S | 1.91 | 382,437 | 729,919 | 720,214 | 1.1 M to 720.2 K (-34.68 %) |
| Aug 25 2017 | HTGM | HTG MOLECULAR DIAG ... | Novo Holdings A/S | 10% Owner | Sell | S | 2.02 | 47,162 | 95,475 | 1,102,651 | 1.1 M to 1.1 M (-4.10 %) |
| Aug 24 2017 | HTGM | HTG MOLECULAR DIAG ... | LAFRANCE JAMES T | Director | Grant | A | 2.05 | 7,500 | 15,375 | 7,500 | 0 to 7.5 K |
| Aug 24 2017 | HTGM | HTG MOLECULAR DIAG ... | HARDISON DON M | Director | Grant | A | 2.05 | 7,500 | 15,375 | 7,500 | 0 to 7.5 K |
| Aug 24 2017 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Grant | A | 2.05 | 7,500 | 15,375 | 100,614 | 93.1 K to 100.6 K (+8.05 %) |
| Aug 24 2017 | HTGM | HTG MOLECULAR DIAG ... | Gordon Debra A | V.P. and Chief Lega ... | Grant | A | 2.05 | 1,000 | 2,050 | 40,904 | 39.9 K to 40.9 K (+2.51 %) |
| Aug 22 2017 | HTGM | HTG MOLECULAR DIAG ... | Novo Holdings A/S | 10% Owner | Sell | S | 2.01 | 12,641 | 25,412 | 1,199,599 | 1.2 M to 1.2 M (-1.04 %) |
| Aug 22 2017 | HTGM | HTG MOLECULAR DIAG ... | Novo Holdings A/S | 10% Owner | Sell | S | 2.02 | 12,845 | 25,976 | 1,212,240 | 1.2 M to 1.2 M (-1.05 %) |
| Aug 22 2017 | HTGM | HTG MOLECULAR DIAG ... | Novo Holdings A/S | 10% Owner | Sell | S | 2.10 | 55,100 | 115,600 | 1,225,085 | 1.3 M to 1.2 M (-4.30 %) |
| Aug 16 2017 | HTGM | HTG MOLECULAR DIAG ... | Shuster Lewis | Director | Option Exercise | A | 2.27 | 6,000 | 13,620 | 6,000 | |
| Aug 16 2017 | HTGM | HTG MOLECULAR DIAG ... | McCracken Lee R. | Director | Option Exercise | A | 2.27 | 6,000 | 13,620 | 6,000 | |
| Aug 16 2017 | HTGM | HTG MOLECULAR DIAG ... | LAFRANCE JAMES T | Director | Option Exercise | A | 2.27 | 6,000 | 13,620 | 6,000 | |
| Aug 16 2017 | HTGM | HTG MOLECULAR DIAG ... | HARDISON DON M | Director | Option Exercise | A | 2.27 | 6,000 | 13,620 | 6,000 | |
| Aug 16 2017 | HTGM | HTG MOLECULAR DIAG ... | George Harry A. | Director | Option Exercise | A | 2.27 | 6,000 | 13,620 | 6,000 | |
| Aug 16 2017 | HTGM | HTG MOLECULAR DIAG ... | HANHAM ANN | Director | Option Exercise | A | 2.27 | 6,000 | 13,620 | 6,000 | |
| Jul 17 2017 | HTGM | HTG MOLECULAR DIAG ... | Gordon Debra A | V.P. and Chief Lega ... | Buy | J | 1.79 | 620 | 1,112 | 39,904 | 39.3 K to 39.9 K (+1.58 %) |
| Jul 17 2017 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Buy | J | 1.79 | 901 | 1,616 | 93,114 | 92.2 K to 93.1 K (+0.98 %) |
| Jul 17 2017 | HTGM | HTG MOLECULAR DIAG ... | McMeans Shaun D | VP, Finance & Admin ... | Buy | J | 1.79 | 901 | 1,616 | 42,639 | 41.7 K to 42.6 K (+2.16 %) |
| Jul 17 2017 | HTGM | HTG MOLECULAR DIAG ... | Lubniewski John L | Chief Business Offi ... | Buy | J | 1.79 | 901 | 1,616 | 47,690 | 46.8 K to 47.7 K (+1.93 %) |
| Jul 17 2017 | HTGM | HTG MOLECULAR DIAG ... | Roche Patrick C. | SVP Research & Deve ... | Buy | J | 1.79 | 901 | 1,616 | 41,815 | 40.9 K to 41.8 K (+2.20 %) |
| Mar 29 2017 | HTGM | HTG MOLECULAR DIAG ... | GLAXOSMITHKLINE PLC | Sell | S | 10.15 | 300,000 | 3,045,180 | 792,781 | 1.1 M to 792.8 K (-27.45 %) | |
| Dec 14 2016 | HTGM | HTG MOLECULAR DIAG ... | Roche Patrick C. | SVP Research & Deve ... | Buy | J | 1.83 | 834 | 1,524 | 40,914 | 40.1 K to 40.9 K (+2.08 %) |
| Dec 14 2016 | HTGM | HTG MOLECULAR DIAG ... | McMeans Shaun D | VP, Finance & Admin ... | Buy | J | 1.83 | 834 | 1,524 | 41,738 | 40.9 K to 41.7 K (+2.04 %) |
| Dec 14 2016 | HTGM | HTG MOLECULAR DIAG ... | Lubniewski John L | Chief Business Offi ... | Buy | J | 1.83 | 834 | 1,524 | 46,789 | 46 K to 46.8 K (+1.81 %) |
| Dec 14 2016 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Buy | J | 1.83 | 834 | 1,524 | 92,213 | 91.4 K to 92.2 K (+0.91 %) |
| Dec 14 2016 | HTGM | HTG MOLECULAR DIAG ... | Gordon Debra A | V.P. and Chief Lega ... | Buy | J | 1.83 | 834 | 1,524 | 39,284 | 38.5 K to 39.3 K (+2.17 %) |
| Aug 30 2016 | HTGM | HTG MOLECULAR DIAG ... | Shuster Lewis | Director | Option Exercise | A | 2.46 | 6,000 | 14,760 | 6,000 | |
| Aug 30 2016 | HTGM | HTG MOLECULAR DIAG ... | LAFRANCE JAMES T | Director | Option Exercise | A | 2.46 | 5,000 | 12,300 | 5,000 | |
| Aug 30 2016 | HTGM | HTG MOLECULAR DIAG ... | McCracken Lee R. | Director | Option Exercise | A | 2.46 | 5,000 | 12,300 | 5,000 | |
| Aug 30 2016 | HTGM | HTG MOLECULAR DIAG ... | Roche Patrick C. | SVP Research & Deve ... | Grant | A | 0.00 | 20,000 | 0 | 40,080 | 20.1 K to 40.1 K (+99.60 %) |
| Aug 30 2016 | HTGM | HTG MOLECULAR DIAG ... | McMeans Shaun D | VP, Finance & Admin ... | Grant | A | 0.00 | 20,000 | 0 | 40,904 | 20.9 K to 40.9 K (+95.68 %) |
| Aug 30 2016 | HTGM | HTG MOLECULAR DIAG ... | Lubniewski John L | Chief Business Offi ... | Grant | A | 0.00 | 20,000 | 0 | 45,955 | 26 K to 46 K (+77.06 %) |
| Aug 30 2016 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Grant | A | 0.00 | 40,000 | 0 | 91,379 | 51.4 K to 91.4 K (+77.85 %) |
| Aug 30 2016 | HTGM | HTG MOLECULAR DIAG ... | Gordon Debra A | V.P. and Chief Lega ... | Grant | A | 0.00 | 20,000 | 0 | 38,450 | 18.5 K to 38.5 K (+108.40 %) |
| Aug 30 2016 | HTGM | HTG MOLECULAR DIAG ... | George Harry A. | Director | Option Exercise | A | 2.46 | 6,000 | 14,760 | 6,000 | |
| Aug 29 2016 | HTGM | HTG MOLECULAR DIAG ... | Shuster Lewis | Director | Option Exercise | A | 2.61 | 6,000 | 15,660 | 6,000 | |
| Aug 29 2016 | HTGM | HTG MOLECULAR DIAG ... | McCracken Lee R. | Director | Option Exercise | A | 2.61 | 6,000 | 15,660 | 6,000 | |
| Aug 29 2016 | HTGM | HTG MOLECULAR DIAG ... | LAFRANCE JAMES T | Director | Option Exercise | A | 2.61 | 6,000 | 15,660 | 6,000 | |
| Aug 29 2016 | HTGM | HTG MOLECULAR DIAG ... | HARDISON DON M | Director | Option Exercise | A | 2.61 | 6,000 | 15,660 | 6,000 | |
| Aug 29 2016 | HTGM | HTG MOLECULAR DIAG ... | George Harry A. | Director | Option Exercise | A | 2.61 | 6,000 | 15,660 | 6,000 | |
| Aug 29 2016 | HTGM | HTG MOLECULAR DIAG ... | HANHAM ANN | Director | Option Exercise | A | 2.61 | 10,000 | 26,100 | 10,000 | |
| Jun 14 2016 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Buy | J | 2.54 | 608 | 1,545 | 51,379 | 50.8 K to 51.4 K (+1.20 %) |
| Jun 14 2016 | HTGM | HTG MOLECULAR DIAG ... | Roche Patrick C. | SVP Research & Deve ... | Buy | J | 2.54 | 928 | 2,359 | 20,080 | 19.2 K to 20.1 K (+4.85 %) |
| Jun 14 2016 | HTGM | HTG MOLECULAR DIAG ... | Lubniewski John L | Chief Business Offi ... | Buy | J | 2.54 | 928 | 2,359 | 25,955 | 25 K to 26 K (+3.71 %) |
| Jun 14 2016 | HTGM | HTG MOLECULAR DIAG ... | McMeans Shaun D | VP, Finance & Admin ... | Buy | J | 2.54 | 928 | 2,359 | 20,904 | 20 K to 20.9 K (+4.65 %) |
| Jun 14 2016 | HTGM | HTG MOLECULAR DIAG ... | Gordon Debra A | V.P. and Chief Lega ... | Buy | J | 2.54 | 928 | 2,359 | 18,450 | 17.5 K to 18.5 K (+5.30 %) |
| May 03 2016 | HTGM | HTG MOLECULAR DIAG ... | HARDISON DON M | Director | Option Exercise | A | 2.80 | 10,000 | 28,000 | 10,000 | |
| Apr 05 2016 | HTGM | HTG MOLECULAR DIAG ... | Lubniewski John L | Chief Business Offi ... | Sell | S | 2.92 | 87 | 254 | 25,027 | 25.1 K to 25 K (-0.35 %) |
| Apr 05 2016 | HTGM | HTG MOLECULAR DIAG ... | Lubniewski John L | Chief Business Offi ... | Sell | S | 2.89 | 709 | 2,048 | 25,114 | 25.8 K to 25.1 K (-2.75 %) |
| Apr 05 2016 | HTGM | HTG MOLECULAR DIAG ... | McMeans Shaun D | VP, Finance & Admin ... | Sell | S | 2.92 | 175 | 512 | 19,976 | 20.2 K to 20 K (-0.87 %) |
| Apr 05 2016 | HTGM | HTG MOLECULAR DIAG ... | McMeans Shaun D | VP, Finance & Admin ... | Sell | S | 2.89 | 1,426 | 4,119 | 20,151 | 21.6 K to 20.2 K (-6.61 %) |
| Apr 05 2016 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Sell | S | 2.92 | 538 | 1,573 | 50,771 | 51.3 K to 50.8 K (-1.05 %) |
| Apr 05 2016 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Sell | S | 2.89 | 4,376 | 12,641 | 51,309 | 55.7 K to 51.3 K (-7.86 %) |
| Apr 05 2016 | HTGM | HTG MOLECULAR DIAG ... | Gordon Debra A | V.P. and Chief Lega ... | Sell | S | 2.92 | 183 | 535 | 17,522 | 17.7 K to 17.5 K (-1.03 %) |
| Apr 05 2016 | HTGM | HTG MOLECULAR DIAG ... | Gordon Debra A | V.P. and Chief Lega ... | Sell | S | 2.89 | 1,489 | 4,301 | 17,705 | 19.2 K to 17.7 K (-7.76 %) |
| Mar 14 2016 | HTGM | HTG MOLECULAR DIAG ... | Roche Patrick C. | SVP Research & Deve ... | Sell | S | 2.19 | 111 | 243 | 19,152 | 19.3 K to 19.2 K (-0.58 %) |
| Mar 14 2016 | HTGM | HTG MOLECULAR DIAG ... | Roche Patrick C. | SVP Research & Deve ... | Sell | S | 2.36 | 4,520 | 10,646 | 19,263 | 23.8 K to 19.3 K (-19.01 %) |
| Mar 14 2016 | HTGM | HTG MOLECULAR DIAG ... | Roche Patrick C. | SVP Research & Deve ... | Sell | S | 2.49 | 1,298 | 3,232 | 23,783 | 25.1 K to 23.8 K (-5.18 %) |
| Mar 14 2016 | HTGM | HTG MOLECULAR DIAG ... | McMeans Shaun D | VP, Finance & Admin ... | Sell | S | 2.19 | 109 | 238 | 21,577 | 21.7 K to 21.6 K (-0.50 %) |
| Mar 14 2016 | HTGM | HTG MOLECULAR DIAG ... | McMeans Shaun D | VP, Finance & Admin ... | Sell | S | 2.36 | 4,305 | 10,140 | 21,686 | 26 K to 21.7 K (-16.56 %) |
| Mar 14 2016 | HTGM | HTG MOLECULAR DIAG ... | McMeans Shaun D | VP, Finance & Admin ... | Sell | S | 2.49 | 1,237 | 3,081 | 25,991 | 27.2 K to 26 K (-4.54 %) |
| Mar 14 2016 | HTGM | HTG MOLECULAR DIAG ... | Lubniewski John L | Chief Business Offi ... | Sell | S | 2.19 | 113 | 247 | 25,823 | 25.9 K to 25.8 K (-0.44 %) |
| Mar 14 2016 | HTGM | HTG MOLECULAR DIAG ... | Lubniewski John L | Chief Business Offi ... | Sell | S | 2.36 | 5,264 | 12,399 | 25,936 | 31.2 K to 25.9 K (-16.87 %) |
| Mar 14 2016 | HTGM | HTG MOLECULAR DIAG ... | Lubniewski John L | Chief Business Offi ... | Sell | S | 2.49 | 1,512 | 3,765 | 31,200 | 32.7 K to 31.2 K (-4.62 %) |
| Mar 14 2016 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Sell | S | 2.19 | 125 | 273 | 55,685 | 55.8 K to 55.7 K (-0.22 %) |
| Mar 14 2016 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Sell | S | 2.36 | 8,154 | 19,206 | 55,810 | 64 K to 55.8 K (-12.75 %) |
| Mar 14 2016 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Sell | S | 2.49 | 2,342 | 5,832 | 63,964 | 66.3 K to 64 K (-3.53 %) |
| Mar 14 2016 | HTGM | HTG MOLECULAR DIAG ... | Gordon Debra A | V.P. and Chief Lega ... | Sell | S | 2.19 | 109 | 238 | 19,194 | 19.3 K to 19.2 K (-0.56 %) |
| Mar 14 2016 | HTGM | HTG MOLECULAR DIAG ... | Gordon Debra A | V.P. and Chief Lega ... | Sell | S | 2.36 | 4,215 | 9,928 | 19,303 | 23.5 K to 19.3 K (-17.92 %) |
| Mar 14 2016 | HTGM | HTG MOLECULAR DIAG ... | Gordon Debra A | V.P. and Chief Lega ... | Sell | S | 2.49 | 1,211 | 3,016 | 23,518 | 24.7 K to 23.5 K (-4.90 %) |
| Mar 09 2016 | HTGM | HTG MOLECULAR DIAG ... | McMeans Shaun D | VP, Finance & Admin ... | Sell | S | 2.69 | 3,325 | 8,933 | 27,228 | 30.6 K to 27.2 K (-10.88 %) |
| Mar 09 2016 | HTGM | HTG MOLECULAR DIAG ... | Roche Patrick C. | SVP Research & Deve ... | Sell | S | 2.69 | 3,491 | 9,379 | 25,081 | 28.6 K to 25.1 K (-12.22 %) |
| Mar 09 2016 | HTGM | HTG MOLECULAR DIAG ... | Lubniewski John L | Chief Business Offi ... | Sell | S | 2.69 | 4,067 | 10,927 | 32,712 | 36.8 K to 32.7 K (-11.06 %) |
| Mar 09 2016 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Sell | S | 2.69 | 6,299 | 16,924 | 66,306 | 72.6 K to 66.3 K (-8.68 %) |
| Mar 09 2016 | HTGM | HTG MOLECULAR DIAG ... | Gordon Debra A | V.P. and Chief Lega ... | Sell | S | 2.69 | 3,256 | 8,748 | 24,729 | 28 K to 24.7 K (-11.63 %) |
| Mar 08 2016 | HTGM | HTG MOLECULAR DIAG ... | Roche Patrick C. | SVP Research & Deve ... | Grant | A | 0.00 | 22,072 | 0 | 28,572 | 6.5 K to 28.6 K (+339.57 %) |
| Mar 08 2016 | HTGM | HTG MOLECULAR DIAG ... | McMeans Shaun D | VP, Finance & Admin ... | Grant | A | 0.00 | 21,021 | 0 | 30,553 | 9.5 K to 30.6 K (+220.53 %) |
| Mar 08 2016 | HTGM | HTG MOLECULAR DIAG ... | Lubniewski John L | Chief Business Offi ... | Grant | A | 0.00 | 25,708 | 0 | 36,779 | 11.1 K to 36.8 K (+232.21 %) |
| Mar 08 2016 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Grant | A | 0.00 | 43,795 | 0 | 72,605 | 28.8 K to 72.6 K (+152.01 %) |
| Mar 08 2016 | HTGM | HTG MOLECULAR DIAG ... | Gordon Debra A | V.P. and Chief Lega ... | Grant | A | 0.00 | 20,583 | 0 | 27,985 | 7.4 K to 28 K (+278.07 %) |
| Feb 17 2016 | HTGM | HTG MOLECULAR DIAG ... | Gordon Debra A | V.P. and Chief Lega ... | Option Exercise | A | 2.36 | 50,000 | 118,000 | 50,000 | |
| Feb 17 2016 | HTGM | HTG MOLECULAR DIAG ... | Roche Patrick C. | SVP Research & Deve ... | Option Exercise | A | 2.36 | 85,000 | 200,600 | 85,000 | |
| Feb 17 2016 | HTGM | HTG MOLECULAR DIAG ... | Lubniewski John L | Chief Business Offi ... | Option Exercise | A | 2.36 | 35,000 | 82,600 | 35,000 | |
| Feb 17 2016 | HTGM | HTG MOLECULAR DIAG ... | McMeans Shaun D | VP, Finance & Admin ... | Option Exercise | A | 2.36 | 20,000 | 47,200 | 20,000 | |
| Feb 17 2016 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Option Exercise | A | 2.36 | 105,000 | 247,800 | 105,000 | |
| Dec 14 2015 | HTGM | HTG MOLECULAR DIAG ... | McMeans Shaun D | VP, Finance & Admin ... | Grant | A | 4.78 | 1,046 | 5,000 | 9,532 | 8.5 K to 9.5 K (+12.33 %) |
| Dec 14 2015 | HTGM | HTG MOLECULAR DIAG ... | Gordon Debra A | V.P. and Chief Lega ... | Grant | A | 4.78 | 1,046 | 5,000 | 7,402 | 6.4 K to 7.4 K (+16.46 %) |
| Dec 14 2015 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Grant | A | 4.78 | 2,092 | 10,000 | 28,810 | 26.7 K to 28.8 K (+7.83 %) |
| Dec 07 2015 | HTGM | HTG MOLECULAR DIAG ... | McCracken Lee R. | Director | Option Exercise | A | 5.05 | 5,000 | 25,250 | 5,000 | |
| Dec 02 2015 | HTGM | HTG MOLECULAR DIAG ... | LAFRANCE JAMES T | Director | Option Exercise | A | 4.88 | 5,000 | 24,400 | 5,000 | |
| Aug 31 2015 | HTGM | HTG MOLECULAR DIAG ... | Lubniewski John L | Chief Business Offi ... | Grant | A | 0.00 | 2,500 | 0 | 11,071 | 8.6 K to 11.1 K (+29.17 %) |
| Aug 31 2015 | HTGM | HTG MOLECULAR DIAG ... | McMeans Shaun D | VP, Finance & Admin ... | Grant | A | 0.00 | 5,000 | 0 | 8,486 | 3.5 K to 8.5 K (+143.43 %) |
| Aug 31 2015 | HTGM | HTG MOLECULAR DIAG ... | Gordon Debra A | V.P. and Chief Lega ... | Grant | A | 0.00 | 5,000 | 0 | 6,356 | 1.4 K to 6.4 K (+368.73 %) |
| Aug 31 2015 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Grant | A | 0.00 | 15,000 | 0 | 26,718 | 11.7 K to 26.7 K (+128.01 %) |
| Aug 25 2015 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Buy | P | 5.34 | 1,000 | 5,341 | 11,718 | 10.7 K to 11.7 K (+9.33 %) |
| Aug 24 2015 | HTGM | HTG MOLECULAR DIAG ... | Gordon Debra A | V.P. and Chief Lega ... | Buy | P | 5.16 | 1,000 | 5,160 | 1,356 | 356 to 1.4 K (+280.90 %) |
| Aug 19 2015 | HTGM | HTG MOLECULAR DIAG ... | Roche Patrick C. | SVP Research & Deve ... | Buy | P | 5.75 | 5,800 | 33,350 | 6,500 | 700 to 6.5 K (+828.57 %) |
| Aug 19 2015 | HTGM | HTG MOLECULAR DIAG ... | Roche Patrick C. | SVP Research & Deve ... | Buy | P | 5.83 | 100 | 583 | 700 | 600 to 700 (+16.67 %) |
| Aug 19 2015 | HTGM | HTG MOLECULAR DIAG ... | Roche Patrick C. | SVP Research & Deve ... | Buy | P | 5.84 | 400 | 2,336 | 600 | 200 to 600 (+200.00 %) |
| Aug 19 2015 | HTGM | HTG MOLECULAR DIAG ... | Roche Patrick C. | SVP Research & Deve ... | Buy | P | 5.83 | 200 | 1,166 | 200 | 0 to 200 |
| Aug 13 2015 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Buy | P | 7.31 | 300 | 2,193 | 10,718 | 10.4 K to 10.7 K (+2.88 %) |
| Aug 13 2015 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Buy | P | 7.46 | 300 | 2,238 | 10,418 | 10.1 K to 10.4 K (+2.97 %) |
| Aug 13 2015 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Buy | P | 7.62 | 2,000 | 15,240 | 10,118 | 8.1 K to 10.1 K (+24.64 %) |
| Aug 13 2015 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Buy | P | 7.48 | 2,400 | 17,952 | 8,118 | 5.7 K to 8.1 K (+41.97 %) |
| Aug 12 2015 | HTGM | HTG MOLECULAR DIAG ... | McMeans Shaun D | VP, Finance & Admin ... | Buy | P | 7.50 | 650 | 4,875 | 3,486 | 2.8 K to 3.5 K (+22.92 %) |
| Aug 12 2015 | HTGM | HTG MOLECULAR DIAG ... | Lubniewski John L | Chief Business Offi ... | Buy | P | 7.50 | 14 | 105 | 8,571 | 8.6 K to 8.6 K (+0.16 %) |
| Aug 12 2015 | HTGM | HTG MOLECULAR DIAG ... | Lubniewski John L | Chief Business Offi ... | Buy | P | 7.67 | 4,986 | 38,243 | 8,557 | 3.6 K to 8.6 K (+139.62 %) |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | Merck Capital Ventures LLC | 10% Owner | Option Exercise | C | 14.00 | 28,436 | 398,104 | 28,436 | |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | Merck Capital Ventures LLC | 10% Owner | Option Exercise | C | 0.22 | 1,818,681 | 398,109 | 0 | |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | Merck Capital Ventures LLC | 10% Owner | Option Exercise | C | 0.00 | 210,893 | 0 | 0 | |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | Merck Capital Ventures LLC | 10% Owner | Option Exercise | X | 0.00 | 210,893 | 0 | 210,893 | |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | Merck Capital Ventures LLC | 10% Owner | Option Exercise | X | 0.00 | 210,893 | 0 | 0 | |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | Merck Capital Ventures LLC | 10% Owner | Option Exercise | C | 0.00 | 7,613,826 | 0 | 0 | |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | Merck Capital Ventures LLC | 10% Owner | Option Exercise | C | 0.00 | 20,658,958 | 0 | 0 | |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | Merck Capital Ventures LLC | 10% Owner | Option Exercise | C | 0.00 | 9,601,924 | 0 | 0 | |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | Merck Capital Ventures LLC | 10% Owner | Option Exercise | C | 0.00 | 8,670,520 | 0 | 0 | |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | Merck Capital Ventures LLC | 10% Owner | Buy | P | 14.00 | 167,343 | 2,342,802 | 756,704 | 589.4 K to 756.7 K (+28.39 %) |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | Merck Capital Ventures LLC | 10% Owner | Buy | J | 0.00 | 52,929 | 0 | 589,361 | 536.4 K to 589.4 K (+9.87 %) |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | Merck Capital Ventures LLC | 10% Owner | Buy | J | 14.00 | 55,377 | 775,278 | 536,432 | 481.1 K to 536.4 K (+11.51 %) |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | Merck Capital Ventures LLC | 10% Owner | Buy | C | 0.00 | 1,963 | 0 | 481,055 | 479.1 K to 481.1 K (+0.41 %) |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | Merck Capital Ventures LLC | 10% Owner | Buy | C | 0.00 | 70,898 | 0 | 479,092 | 408.2 K to 479.1 K (+17.37 %) |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | Merck Capital Ventures LLC | 10% Owner | Buy | C | 0.00 | 192,373 | 0 | 408,194 | 215.8 K to 408.2 K (+89.14 %) |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | Merck Capital Ventures LLC | 10% Owner | Buy | C | 0.00 | 90,494 | 0 | 215,821 | 125.3 K to 215.8 K (+72.21 %) |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | Merck Capital Ventures LLC | 10% Owner | Buy | C | 0.00 | 125,327 | 0 | 125,327 | 0 to 125.3 K |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | McMeans Shaun D | VP, Finance & Admin ... | Option Exercise | C | 0.00 | 152,276 | 0 | 0 | |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | McMeans Shaun D | VP, Finance & Admin ... | Option Exercise | C | 0.00 | 114,207 | 0 | 0 | |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | McMeans Shaun D | VP, Finance & Admin ... | Buy | J | 0.00 | 356 | 0 | 2,836 | 2.5 K to 2.8 K (+14.35 %) |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | McMeans Shaun D | VP, Finance & Admin ... | Buy | C | 0.00 | 1,417 | 0 | 2,480 | 1.1 K to 2.5 K (+133.30 %) |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | McMeans Shaun D | VP, Finance & Admin ... | Buy | C | 0.00 | 1,063 | 0 | 1,063 | 0 to 1.1 K |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | Lubniewski John L | Chief Business Offi ... | Option Exercise | C | 0.00 | 76,138 | 0 | 0 | |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | Lubniewski John L | Chief Business Offi ... | Option Exercise | C | 0.00 | 228,414 | 0 | 0 | |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | Lubniewski John L | Chief Business Offi ... | Buy | J | 0.00 | 737 | 0 | 3,571 | 2.8 K to 3.6 K (+26.01 %) |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | Lubniewski John L | Chief Business Offi ... | Buy | C | 0.00 | 708 | 0 | 2,834 | 2.1 K to 2.8 K (+33.30 %) |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | Lubniewski John L | Chief Business Offi ... | Buy | C | 0.00 | 2,126 | 0 | 2,126 | 0 to 2.1 K |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Option Exercise | C | 0.00 | 10,544 | 0 | 0 | |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Option Exercise | X | 0.00 | 10,544 | 0 | 10,544 | |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Option Exercise | X | 0.00 | 10,544 | 0 | 0 | |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Option Exercise | C | 0.00 | 60,910 | 0 | 0 | |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Option Exercise | C | 0.00 | 233,495 | 0 | 0 | |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Option Exercise | C | 0.00 | 221,631 | 0 | 0 | |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Buy | J | 0.00 | 791 | 0 | 5,718 | 4.9 K to 5.7 K (+16.05 %) |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Buy | C | 0.00 | 98 | 0 | 4,927 | 4.8 K to 4.9 K (+2.03 %) |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Buy | C | 0.00 | 567 | 0 | 4,829 | 4.3 K to 4.8 K (+13.30 %) |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Buy | C | 0.00 | 2,174 | 0 | 4,262 | 2.1 K to 4.3 K (+104.12 %) |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | JOHNSON TIM B | President & CEO | Buy | C | 0.00 | 2,088 | 0 | 2,088 | 0 to 2.1 K |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | GRIMM DONALD W | Director | Option Exercise | A | 14.64 | 5,000 | 73,200 | 5,000 | |
| May 13 2015 | HTGM | HTG MOLECULAR DIAG ... | Gordon Debra A | V.P. and Chief Lega ... | Option Exercise | C | 0.00 | 7,646 | 0 | 0 |